Power Wheelchair Group 2 denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's Commercial policy states that mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POVs), canes, and walkers are a covered health care service when medically necessary. The policy applies the Medicare DME MAC LCD for Power Mobility Devices (L33789) criteria, which require that the beneficiary has a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home, where the mobility limitation prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completion within a reasonable time frame. The beneficiary's mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. For a Group 2 Single Power Option PWC (K0835–K0840), all basic coverage criteria (a)–(e) must be met, plus the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick (e.g., head control, sip and puff, switch control), OR meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair, AND has had a specialty evaluation performed by a licensed/certified medical professional (PT, OT, or practitioner) with specific training and experience in rehabilitation wheelchair evaluations documenting medical necessity. The wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. Section 6407 of the ACA requires a face-to-face encounter, documented by a physician (or NP, PA, or CNS), occurring within the 6 months before the order is written for the DME. Weight-class criteria apply: a Heavy Duty PWC is covered for beneficiaries weighing 285–450 pounds, Very Heavy Duty for 428–600 pounds, and Extra Heavy Duty for 570 pounds or more. Payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document in-home MRADL impairment in detail** — Provide specific examples of how the member cannot independently/safely complete toileting, feeding, dressing, grooming, or bathing in the home, mapping directly to the LCD MRADL definition: a mobility limitation that prevents accomplishment of an MRADL, places the beneficiary at heightened risk of morbidity/mortality, or prevents completion within a reasonable time frame. - **Demonstrate failure of lesser alternatives** — Include PT/OT trial documentation showing that the beneficiary lacks sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day due to weakness, fatigue, pain, ROM limits, or absent extremities, satisfying LCD basic criterion C. - **Submit a compliant specialty evaluation and ATP attestation** — Provide the LCMP/PT/OT evaluation with the no-financial-relationship attestation per the requirement of a signed and dated attestation by the supplier or LCMP that the LCMP has no financial relationship with the supplier , plus documentation that the wheelchair is provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) who specializes in wheelchairs and has direct, in-person involvement in the wheelchair selection. - **Justify the Group 2 power option upgrade** — For K0835–K0840, document either a non-standard drive control need (head control, sip-and-puff, switch) OR concurrent need for a power tilt/recline system per the LCD requirement that the beneficiary requires a drive control interface other than a hand or chin-operated standard proportional joystick, or meets coverage criteria for a power tilt or power recline seating system being used on the wheelchair. - **Provide a timely 7-element order and face-to-face note** — Submit the in-window F2F note and order; per the LCD policy article, the 7-element order must be received by the supplier within 45 days after completion of the face-to-face examination , and per CMS, the encounter must occur within the 6 months before the order is written. - **Verify accurate weight-class coding** — Confirm the member's weight aligns with the prescribed class boundaries set by the LCD: Heavy Duty 285–450 lb, Very Heavy Duty 428–600 lb, and Extra Heavy Duty 570 lb or more , and amend the HCPCS code if a misclassification triggered the denial. - **Cite clinical/professional standards** — Reference RESNA's position papers on the application of power wheelchairs and seat-elevation/tilt systems, and AOTA/APTA wheelchair assessment guidelines, to support the medical necessity narrative that mirrors LCD L33789 — the framework UnitedHealthcare explicitly adopts via its Mobility Devices policy and the DME MAC LCD for Power Mobility Devices (L33789).

## Why UnitedHealthcare Labeled Your Group 2 Power Wheelchair "Experimental" — and Why That Label Is Almost Always Wrong

An "experimental/investigational" denial on HCPCS K0835–K0843 is a category error. Group 2 power wheelchairs are not investigational devices — they are established Medicare benefits with their own LCD (L33789), Policy Article (A52498), and decades of CMS payment history. When UnitedHealthcare Medicare Advantage stamps "experimental" on a Group 2 PWC, what is actually happening is one of three things: (1) the reviewer is denying a specific feature (power tilt, power recline, alternative drive control, elevating seat) as not yet evidence-based; (2) the reviewer is rejecting the specialty evaluation from the PT/OT/ATP as insufficient documentation of medical necessity; or (3) the chair was upcoded from Group 2 Single Power Option (K0835–K0840) to Multiple Power Option (K0841–K0843) without the underlying neurological condition, myopathy, congenital skeletal deformity, or ventilator-dependence required by LCD L33789.

Under 42 CFR §422.101(b), a Medicare Advantage plan cannot apply coverage criteria more restrictive than Original Medicare. LCD L33789 governs — period. UHC's Medicare Advantage Coverage Summary: DME, Prosthetics, Orthotics, Nutritional Therapy and Medical Supplies Grid explicitly delegates Group 2 PWC adjudication to the applicable DME MAC LCD. If the LCD criteria (a)–(e) are met and the specialty evaluation documents an MRADL deficit that cannot be resolved by a cane, walker, manual chair, or POV, the "experimental" label is unsustainable. CMS Internet-Only Manual Pub. 100-08 Ch. 5 §5.7 forbids contractors from inventing extra-LCD criteria.

Procedurally, route the appeal through UHC's MA reconsideration channel under 42 CFR §422.566 and §422.582, not the commercial Optum/pharmacy pipeline. Demand the specific LCD criterion UHC claims is unmet — "experimental" is not a permissible denial basis for a covered benefit category under §422.566(b). On Level 2, the Independent Review Entity (currently MAXIMUS Federal Services / C2C Innovative Solutions for Part C DME) reviews de novo and routinely overturns mislabeled experimental denials when the LCD checklist is satisfied.

For ERISA-governed UHC commercial plans, Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) places the burden on the plan to produce the clinical evidence supporting an experimental determination — boilerplate denial letters that fail to identify which specific component is investigational violate 29 CFR §2560.503-1(g)(1)(v)(B).

Tactical tip: Attach the seven-element Standard Written Order, the LCMP/ATP specialty evaluation, the face-to-face encounter note dated within 6 months of the SWO, and a point-by-point LCD L33789 criteria matrix. Then cite the exact LCD section UHC failed to address. If the reviewer cannot point to a specific component coded outside L33789's covered HCPCS list, escalate to the IRE on day 61 and file a parallel complaint with your state DOI and CMS Region office (1-800-MEDICARE) referencing 42 CFR §422.504(a)(3)(iii) — failure to follow CMS coverage rules is a contract violation.